A Study of Timunox (Thymopentin) in HIV-Infected Patients Receiving Other Anti-HIV Drugs

The Incidence and Severity of Drug Interactions Before and After Switching Antiretroviral Therapy to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Treatment Experienced Patients

NCT03789968 ·Status: COMPLETED

Innovation-TiFP4-C101: A Study to Evaluate the Pharmacokinetics of TMC114 and TMC41629 After a Single Oral Dose of 2 Controlled-release Coformulations as Compared to an Immediate-release Coformulation of TMC114/TMC41629

NCT00854204 ·Status: COMPLETED ·Phase: PHASE1

A Safety and Efficacy Study of Amdoxovir in HIV-1 Treatment-experienced Subjects.

NCT01737359 ·Status: TERMINATED ·Phase: PHASE2

TMB-365 and TMB-380 in Suppressed HIV-1 Infected Individuals

NCT05275998 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

TMC278-TiDP15-C158 - A Study to Examine the Safety, Tolerability and Pharmacokinetics of a Single Dose or Three Successive Doses of Intramuscularly (IM) Injected Long Acting Formulation of TMC278

NCT01031589 ·Status: COMPLETED ·Phase: PHASE1

The Safety of Tenofovir Disoproxil Fumarate Taken With Other Anti-HIV Drugs to Treat HIV-Infected Patients

NCT00007436 ·Status: UNKNOWN ·Phase: PHASE3

TMC125-C216: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00255099 ·Status: COMPLETED ·Phase: PHASE3

Drug Drug Interaction of BI 201335 and Tenofovir

NCT01340196 ·Status: COMPLETED ·Phase: PHASE1

TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use

NCT00225303 ·Status: COMPLETED ·Phase: PHASE2

Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Adults Who Are Virologically Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)

NCT02345252 ·Status: COMPLETED ·Phase: PHASE3

PEPI-TiDP23-C103: First-in-Human Study to Examine the Safety, Tolerability, and Plasma Pharmacokinetics of Increasing Single and Repeated Oral Doses of TMC558445 and of a Combined Single Day Dosing of Oral TMC558445 and Oral TMC310911 and Also Oral Darunavir

NCT00838760 ·Status: COMPLETED ·Phase: PHASE1

PEPI-TiDP23-C104 is a First in Human Study With a Single Dose Escalation Part and a Multiple Dosing Part for Compounds TMC589337 and TMC589354.

NCT00908414 ·Status: WITHDRAWN ·Phase: PHASE1

Study to Evaluate the Safety and Efficacy of a Single Tablet Regimen of Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate Compared With a Single Tablet Regimen of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults

NCT01309243 ·Status: COMPLETED ·Phase: PHASE3

TMC114-C209: A Study of Safety of TMC114 With Low Dose Ritonavir (RTV) and Other Antiretrovirals in Experienced HIV-1 Infected Patients With Limited or no Treatment Options

NCT00115050 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of the Safety and Efficacy of Reformulated Raltegravir (MK-0518) 1200 mg Once Daily in Combination With TRUVADA™ in Human Immunodeficiency Virus (HIV)-1 Infected, Treatment-Naive Participants (MK-0518-292)

NCT02131233 ·Status: COMPLETED ·Phase: PHASE3

HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study

NCT07215468 ·Status: RECRUITING ·Phase: PHASE2

TMC278-TiDP15-C150: Trial to Examine Safety, Tolerability and Plasma Pharmacokinetics of Multiple Doses of TMC278LA.

NCT00741741 ·Status: TERMINATED ·Phase: PHASE1

A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

NCT00002269 ·Status: COMPLETED ·Phase: NA

A Study to Evaluate the Safety and Effectiveness of a New Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), (+)-Calanolide A, in HIV-Positive Patients Who Have Never Received Anti-HIV Treatment

NCT00002243 ·Status: COMPLETED ·Phase: PHASE1

An Open Label Trial of TMC114/RTV in HIV-1 Infected, Treatment-experienced Subjects.

NCT00081588 ·Status: COMPLETED ·Phase: PHASE2

TMC125-C206: A Phase III Study to Investigate the Efficacy, Tolerability and Safety of TMC125 as Part of an Antiretroviral Regimen, Including TMC114/Ritonavir and an Investigator-selected Optimized Background, in HIV-1 Infected Patients With Limited to no Treatment Options.

NCT00254046 ·Status: COMPLETED ·Phase: PHASE3

TMC125-C223: TMC125 in HIV-1 Infected Subjects

NCT00081978 ·Status: COMPLETED ·Phase: PHASE2

A Phase I/II Trial of Ribavirin (With Escalation) + Isoprinosine in Asymptomatic HIV-Viremic Patients

NCT00000699 ·Status: COMPLETED ·Phase: PHASE1

TMC125-C211: Trial of TMC125 in HIV-1 Infected Subjects Who Were in a Sponsor Selected TMC125 Trial

NCT00111280 ·Status: COMPLETED ·Phase: PHASE2

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

NCT00127959 ·Status: COMPLETED ·Phase: PHASE4